Weekly Recap: HS-10374 Phase—III success and Risvutatug NMPA priority

Hansoh Pharmaceutical Group Company Limited (HKEX:3692) advanced two programs: HS-10374 hit co-primary endpoints in a Phase III plaque psoriasis trial, while Risvutatug Rezetecan injection earned NMPA priority review for osteosarcoma, accelerating both toward next development and regulatory milesto…